Skip to main content

IBM and Spotfire Announce Alliance, Sign Aventis as First Client for Combined Offering

NEW YORK, June 25 - IBM and Spotfire said Monday they would work together to combine Spotfire's software with IBM's back-end information management, data integration, and computing infrastructure. 

The companies also said that Aventis would be the first customer to use this combination of Spotfire's DecisionSite analysis platform and IBM's DiscoveryLink integration middleware. 

Financial terms for the partnerships were not disclosed.

Under the IBM/Spotfire alliance, Spotfire will optimize its current and future applications for IBM platforms and middleware, including the DB2 database and DiscoveryLink.

Aventis will use DiscoveryLink to manage and integrate data from multiple biological and chemical databases and will use DecisionSite to allow researchers to query those databases and identify new drug targets. The company said it expects this combination of techniques to reduce its drug innovation and approval from 10-15 years to six to nine years.

Spotfire also has partnerships to integrate DecisionSite with products from Micromass and Celera, while IBM has partnerships to integrate DiscoveryLink with products from Micromass, LabBook, and NetGenics.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.